|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-4-1
|
|
pubmed:abstractText |
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are gaining an increasing role in the management of advanced non-small cell lung cancer (NSCLC). There is mounting interest in the benefit of administering a second TKI after failure of the first TKI, especially in Asian patients, in whom they are expected to be more efficacious.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
400-4
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18379359-Adult,
pubmed-meshheading:18379359-Aged,
pubmed-meshheading:18379359-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18379359-Disease Progression,
pubmed-meshheading:18379359-Female,
pubmed-meshheading:18379359-Humans,
pubmed-meshheading:18379359-Lung Neoplasms,
pubmed-meshheading:18379359-Lymphatic Metastasis,
pubmed-meshheading:18379359-Male,
pubmed-meshheading:18379359-Middle Aged,
pubmed-meshheading:18379359-Mutation,
pubmed-meshheading:18379359-Protein Kinase Inhibitors,
pubmed-meshheading:18379359-Quinazolines,
pubmed-meshheading:18379359-Receptor, Epidermal Growth Factor,
pubmed-meshheading:18379359-Retrospective Studies,
pubmed-meshheading:18379359-Survival Rate
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
|
|
pubmed:affiliation |
Department of Haematology-Oncology, National University Hospital, Singapore. Alvin_SC_WONG@nuh.com.sg
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
